STAHL NEIL
SEC CIK 1226689 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals | EVP Research, Development | 48.8K | — | $37.65M | 30 | 2021-11-29 | 2024-12-16 |
Most active insiders at REGN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | POON CHRISTINE A | Dir | — | $4.25M |
| 2 | McCourt Marion | EVP Commercial | — | $2.00M |
| 3 | Zoghbi Huda Y | Dir | — | $1.92M |
| 4 | Pitofsky Jason | VP Ctrl | — | $1.87M |
| 5 | Bassler Bonnie L | Dir | — | $1.77M |
| 6 | Guarini Kathryn | Dir | — | $660.0K |
| 7 | RYAN ARTHUR F | Dir | — | $434.7K |
| 8 | MURPHY ANDREW J | EVP Research | — | — |
| 9 | Fenimore Christopher R. | EVP Fin CFO | — | — |
| 10 | Schenkein David P | Dir | — | — |
STAHL NEIL made no open-market trades at REGN in the last 12 months.
Transactions 30
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-18 | 2024-12-16 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | F - Tax | $730.81 | -304 | 48.8K | -0.6% | -$222.2K | |
| 2024-12-10 | 2024-12-09 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | F - Tax | $787.00 | -466 | 49.1K | -0.9% | -$366.7K | |
| 2024-08-14 | 2024-08-13 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | G - Gift | $0.00 | -500 | 49.6K | -1.0% | $0 | |
| 2024-08-12 | 2024-08-12 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | G - Gift | $0.00 | -900 | 50.1K | -2% | $0 | |
| M | 2024-08-12 | 2024-08-08 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | S - Sale | $1,084.54 | -5,197 | 56.1K | -8% | -$5.64M |
| D | 2024-08-06 | 2024-08-02 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | M - OptEx | $555.67 | +23.6K | 74.6K | +46% | +$13.13M |
| D | 2024-08-06 | 2024-08-02 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | F - Tax | $1,093.49 | -18.4K | 56.2K | -25% | -$20.17M |
| 2024-02-28 | 2024-02-26 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | G - Gift | $0.00 | -1,020 | 51.0K | -2% | $0 | |
| M | 2024-02-08 | 2024-02-07 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | S - Sale | $950.35 | -8,037 | 54.3K | -13% | -$7.64M |
| D | 2024-02-06 | 2024-02-02 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | F - Tax | $956.65 | -22.7K | 60.1K | -27% | -$21.73M |
| D | 2024-02-06 | 2024-02-02 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | M - OptEx | $399.66 | +30.8K | 82.8K | +59% | +$12.29M |
| DM | 2023-12-12 | 2023-12-08+ | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | F - Tax | $843.93 | -1,534 | 52.0K | -3% | -$1.29M |
| D | 2023-12-12 | 2023-12-08 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | A - Grant | $0.00 | +853 | 52.7K | +2% | $0 |
| 2023-11-14 | 2023-11-10 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | G - Gift | $0.00 | -400 | 52.7K | -0.8% | $0 | |
| DM | 2023-08-23 | 2023-08-22 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | S - Sale+OE | $840.98 | -11.7K | 58.5K | -17% | -$9.81M |
| D | 2023-08-23 | 2023-08-21 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | M - OptEx | $399.66 | +50.0K | 103.1K | +94% | +$19.98M |
| D | 2023-08-23 | 2023-08-21 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | F - Tax | $833.39 | -38.3K | 64.8K | -37% | -$31.95M |
| D | 2022-12-20 | 2022-12-16 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | A - Grant | $0.00 | +1,101 | 53.1K | +2% | $0 |
| 2022-12-13 | 2022-11-08 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | G - Gift | $0.00 | -330 | 52.5K | -0.6% | $0 | |
| 2022-12-13 | 2022-12-09 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | F - Tax | $753.28 | -466 | 52.0K | -0.9% | -$351.0K | |
| DM | 2022-08-08 | 2022-08-05 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | S - Sale+OE | $612.61 | -23.8K | 53.6K | -31% | -$14.57M |
| D | 2022-08-08 | 2022-02-18 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | G - Gift | $0.00 | -335 | 52.8K | -0.6% | $0 |
| D | 2022-08-08 | 2022-08-04 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | M - OptEx | $270.43 | +95.0K | 147.8K | +180% | +$25.69M |
| D | 2022-08-08 | 2022-08-04 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | F - Tax | $613.00 | -71.2K | 76.6K | -48% | -$43.66M |
| 2021-12-14 | 2021-12-11 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | F - Tax | $664.34 | -753 | 53.1K | -1% | -$500.2K | |
| D | 2021-12-10 | 2021-12-08 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | A - Grant | $0.00 | +2,926 | 53.9K | +6% | $0 |
| D | 2021-12-06 | 2021-12-03 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | M - OptEx | $179.13 | +72.5K | 101.3K | +252% | +$12.99M |
| DI | 2021-12-06 | 2021-11-29 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | G - Gift | $0.00 | +4,605 | 4,605 | New | $0 |
| D | 2021-12-06 | 2021-11-29 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | G - Gift | $0.00 | -4,605 | 28.8K | -14% | $0 |
| D | 2021-12-06 | 2021-12-03 | REGN | Regeneron Pharmaceuticals | STAHL NEIL | EVP Research, Development | F - Tax | $632.45 | -50.4K | 51.0K | -50% | -$31.85M |
Purchase Sale Sale after option exercise All abbreviations